“
“Background and objectiveHigh-mobility group box 1 (HMGB1) is an important mediator in multiple pathological conditions, but the expression of HMGB1 in chronic obstructive pulmonary disease (COPD) has not yet been completely investigated. We aimed to analyze the relationship between HMGB1 expression in blood and lung tissue and the Wnt beta-catenin pathway development of COPD.
MethodsTwenty-eight patients admitted for single pulmonary surgical intervention were enrolled. The expression of HMGB1 in blood and lung tissue was evaluated by enzyme-linked immunosorbent assay
analysis and immunohistochemistry stain, respectively. The study patients were divided into smokers with COPD (n=11), smokers without COPD (n=8) and non-smoker healthy controls (n=9).
ResultsSmokers with COPD compared with smokers without COPD and healthy controls were older in age, with lower post-bronchodilator forced expiratory volume in 1s/forced vital capacity (FEV1/FVC) ratio (63.15.5 vs 77.63.6 and 84.5 +/- 5.8, P<0.001 and P<0.001, respectively) and higher levels of plasma HMGB1 (93.2 +/- 139.9 vs 7.3 +/- 4.8 and 17.0 +/- 19.6ng/mL, P=0.016 and P=0.021, respectively). In smokers with COPD, the numbers and portion of HMGB1-expressing
cells in epithelium and submucosal areas were significantly increased. Notably, plasma HMGB1 levels negatively correlated with post-bronchodilator FEV1/FVC ratio (r=-0.585, P=0.008) in smokers, but not in non-smokers.
ConclusionsIn smokers, high expression of HMGB1 in the blood and lungs is related
to the lung function impairment Cl-amidine inhibitor and YM155 datasheet appears to be associated with the development of COPD.
Our study showed that in individuals with smoking risk factor, high expression of HMGB1 in the blood and lungs is related to the decline of lung function and appears to be associated with the development of COPD.”
“Dr. Goldman is a consultant with Bioniche Pharma Ltd., manufacturer of Sotradecol, and Angiodynamics Inc., distributor of Sotradecol.”
“A highly sensitive and simple LC-MS/MS method after one-step protein precipitation was developed and validated for determination of pidotimod (CAS 121808-62-6) in human plasma using dextrophan (CAS 125-73-5) as internal standard (IS). Pidotimod and IS were separated on a YMC-ODS-AQ C-18 column using 0.5% formic acid and methanol as a mobile phase at a flow rate of 0.3 mL/min. Detection was performed on positive ion mode of the transitions at 245.0 -> 134.0 for pidotimod and 258.1 -> 057.0 for IS by selected reaction monitoring (SRM). The assay exhibited a linear range of 0.05-10.0 mu g/mL. The lower limit of quantification were 0.05 mu g/mL. Validation results indicated that the accuracy as determined from quality control samples was in the range of -4.00-6.48%. Intra-day and inter-day precision was <= 8.35% and <= 8.00%, respectively.